Clinical trials: Clinical Malaria
Malaria
Trial to Evaluate L9LS in Healthy Adults
Background: Malaria is a parasitic disease carried by mosquitoes in tropical areas. There is no vaccine to prevent malaria infection. If not treated right away, it can become serious or deadly.
- Trial name
- VRC 614 (NCT05019729)
- Testing
- VRC-MALMAB0114-00-AB, Plasmodium falciparum (P. falciparum) sporozoite challenge
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Prevention of Malaria Transmission and Clinical Malaria
Dose-Escalating Study of Pfs230D1 in Combination With R21 in Matrix-M in African Adults
This is a Phase 1, individually randomized, double-blind, dose escalating study designed to evaluate the safety, tolerability, and immunogenicity of Pfs230D1 conjugate vaccines, R21 nanoparticle vaccine, or their combination…
- Trial name
- NCT06507605
- Testing
- R21, Pfs230D1-CRM197, Pfs230D1-EPA
- Where
- Mali
- Volunteers
- 240 people, healthy volunteers welcome
- Sponsor
- Serum Institute of India Pvt. Ltd.
Malaria
Pan-Malaria Transmission-Blocking Vaccine AnAPN1
Malaria is still responsible for more than 627,000 deaths each year, predominantly among children under 5 years old. Current reductions in deaths have stagnated, and additional setbacks for malaria control programs due to the…
- Trial name
- PamTBVac (NCT05905432)
- Testing
- Vaccine AnAPN1
- Where
- Gabon
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- Centre de Recherche Médicale de Lambaréné
Malaria
Trial to Evaluate CIS43LS in Healthy Adults
Background: People get malaria when they are bitten by an infected mosquito. Malaria can be serious and sometimes deadly. Although there are medicines to treat malaria, there is no vaccine that fully prevents infection.
- Trial name
- NCT04206332
- Testing
- VRC-MALMAB0100-00-AB, Plasmodium falciparum (P. falciparum) sporozoite challenge
- Where
- 2 sites in United States
- Volunteers
- 71 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Vaccine Reaction
A Trial For The Study of Falciparum Malaria Protein 014 Administered Via Intramuscular Injection in Healthy Adults
A Phase 1, open label clinical study to evaluate the safety, immunogenicity, tolerability and efficacy of Plasmodium falciparum Malaria Protein 014 (FMP014) combined with (ALF with QS-21), saponin molecule derived from the bark…
- Trial name
- NCT04296279
- Testing
- FMP014, ALFQ
- Where
- United States
- Volunteers
- 46 people, healthy volunteers welcome
- Sponsor
- U.S. Army Medical Research and Development Command
Malaria
Safety, Tolerability and Efficacy of PfSPZ Vaccine Against Heterologous CHMI in US Malaria naïve Adults
This is a randomized, double blind, placebo-controlled, single site, trial of a condensed regimen of PfSPZ Vaccine administered on Days 1, 8 and 29 by direct venous inoculation (DVI) to assess safety, tolerability, immunogenicity…
- Trial name
- NCT04966871
- Testing
- PfSPZ Vaccine, PfSPZ Challenge (7G8) for CHMI, Normal Saline
- Where
- United States
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- Sanaria Inc.
Malaria, Vivax
Efficacy of a Synthetic Vaccine Derived From Plasmodium Vivax Circumsporozoite Protein (PvCS) in naïve and Semi-immune Volunteers
This is a randomized, double-blind, controlled, which seeks to compare two groups of volunteers (naive and previously exposed to malaria) vaccinated with three doses of a synthetic derivative of the CS protein of Plasmodium vivax…
- Trial name
- NCT04739917
- Testing
- Vaccine PvCS N+C+R 150 mcg
- Where
- Colombia
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Malaria Vaccine and Drug Development Center
Malaria
Bioequivalence Trial of Pyronaridine Artesunate To-be-marketed Tablet to the Clinical Trial Reference Tablet
The primary objective of this study is to determine the bioequivalence of the combination of pyronaridine and artesunate (180:60mg) to-be-marketed tablet to the clinical trial reference tablet administered as a single total dose…
- Trial name
- NCT00682630
- Testing
- pyronaridine artesunate clinical trial reference tablets, pyronaridine artesunate to-be-marketed tablets
- Where
- Switzerland
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- Medicines for Malaria Venture
Malaria
Phase 1 Clinical Trial With Controlled Human Malaria Infection (CHMI) to Evaluate the Safety and Efficacy of the Plasmodium Falciparum Vaccine Candidate FMP012 Administered Intramuscularly With AS01B Adjuvant System in Healthy Malaria-Naïve Adults
The proposed study is a Phase 1 study with controlled human malaria infection (CHMI) designed primarily to evaluate the safety of the FMP012 combined with AS01B adjuvant system.
- Trial name
- NCT02174978
- Testing
- FMP012 with AS01B adjuvant system, P falciparum Controlled Human Malaria Infection (CHMI)
- Where
- United States
- Volunteers
- 39 people, healthy volunteers welcome
- Sponsor
- U.S. Army Medical Research and Development Command
Plasmodium Vivax Malaria
Clinical Trial for the Development of a Safe Malaria Challenge Model That Can be Reproduced in Humans
The purpose of this study is to demonstrate that volunteers can be safely and reproducibly infected with Plasmodium vivax (P. vivax) by the bites of experimentally infected Anopheles dirus (An. dirus) mosquitoes carrying P.
- Trial name
- Pvivax (NCT00935623)
- Testing
- Malaria Challenge
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- U.S. Army Medical Research and Development Command
Plasmodium Vivax Infection, Plasmodium Vivax Clinical Episode
Effect of Liver and Blood-stage Treatment on Subsequent Plasmodium Reinfection and Morbidity
This study specifically seeks to quantify the contribution of relapes to the burden of P. vivax infections and disease by determining on the effect of radical pre-erythrocytic and erythrocytic clearance on subsequent rates of…
- Conditions
- Plasmodium Vivax Infection, Plasmodium Vivax Clinical Episode, Plasmodium Falciparum Infection, Plasmodium Falciparum Clinical Episode
- Trial name
- NCT02143934
- Testing
- Primaquine, Chloroquine, Artemether Lumefantrine
- Where
- Papua New Guinea
- Volunteers
- 524 people, healthy volunteers welcome
- Sponsor
- Papua New Guinea Institute of Medical Research
Malaria
A Clinical Trial to Assess the Safety and Immunogenicity of New Malaria Vaccine Candidates ChAd63 Pfs25-IMX313 and MVA Pfs25-IMX313
This is a clinical trial in which healthy volunteers will be administered one or two experimental malaria vaccines. ChAd Pfs-IMX313 will either be administered alone or with MVA Pfs25-IMX313 in a prime-boost regime.
- Trial name
- NCT02532049
- Testing
- ChAd63 Pfs25-IMX313, MVA Pfs25-IMX313
- Where
- 2 sites in United Kingdom
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Malaria,Falciparum, Anemia in Children
Comparing Chemoprevention Drugs for School-based Malaria Control
This is an individually randomized, controlled, single blind three arm clinical trial of malaria chemoprevention strategies Arm 1: Intermittent preventive treatment with dihydroartemisinin-piperaquine (IPT-DP).
- Trial name
- NCT05980156
- Testing
- Dihydroartemisinin-Piperaquine, Chloroquine, Sulfadoxine pyrimethamine
- Where
- Malawi
- Volunteers
- 646 people, healthy volunteers welcome
- Sponsor
- University of Maryland, Baltimore
Malaria
Safety and Immunogenicity in Age De-Escalation of PfSPZ Vaccine in Tanzanian Adults, Children, and Infants
The present trial will evaluate safety and tolerability as well as the vaccine-induced humoral and cellular immune responses in healthy Tanzanian adults, adolescents, children, and infants who receive doses of 1.8x10^6, 9.0x10^5…
- Trial name
- NCT02613520
- Testing
- PfSPZ Vaccine, Normal Saline, PfSPZ Challenge (for CHMI)
- Where
- Tanzania
- Volunteers
- 105 people, healthy volunteers welcome
- Sponsor
- Sanaria Inc.
Plasmodium Falciparum, Plasmodium Vivax Malaria
PpPfs25/ISA51 and ScPvs25/ISA51 Vaccines for Malaria
This study, conducted at Johns Hopkins University Center for Immunization Research in Washington DC, will test the safety and immune response of healthy volunteers to two experimental malaria vaccines.
- Trial name
- NCT00295581
- Testing
- PpPfs25/ISA51 & ScPvs25/ISA51
- Where
- 2 sites in United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Malaria
R21/Matrix-M in African Children Against Clinical Malaria
A Phase III randomized controlled multi-centre trial to evaluate the efficacy of the R21/Matrix-M vaccine in African children against clinical malaria
- Trial name
- NCT04704830
- Testing
- R21/Matrix-M, Rabies vaccine, Hepatitis A vaccine or Meningococcal vaccine
- Where
- United Kingdom
- Volunteers
- 4,800 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Malaria
A Clinical Study of Piperaquine, Pyronaridine, and Artesunate Administered in Combination in Healthy Adults
This is an open-label pharmacokinetic study in 24 healthy Thai participants. Participants will be admitted in the inpatient ward and each participant will attend a total of 4 visits, including one screening visit and three…
- Trial name
- APP (NCT07470424)
- Testing
- Piperaquine, Artesunate-pyronaridine (Pyramax), Piperaquine and artesunate-pyronaridine (Pyramax)
- Where
- Thailand
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Febrile Illness Acute, Biomarkers
Clinical Aspects, Management and Surveillance of Febrile Illnesses in DRC
The epidemiology and outcome of febrile illnesses in the Democratic Republic of Congo (DRC) is poorly documented. The FIKI² study, a prospective observational study of community-acquired febrile illnesses coordinated by ITM and…
- Conditions
- Febrile Illness Acute, Biomarkers, Surveillance
- Trial name
- FI-CARE (NCT07345286)
- Where
- Democratic Republic of the Congo
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- Institute of Tropical Medicine, Belgium
Malaria,Falciparum, Morality
An Observational Study to Assess Effectiveness and Safety of The R21/Matrix-M Malaria Vaccine
This is an observational case-control study to assess the effectiveness of the R21/Matrix-M vaccine against severe malaria, clinical malaria (in high transmission perennial areas), and to assess if the R21 vaccine recipients are…
- Trial name
- NCT07009847
- Testing
- Case control study of clinical malaria, Case control study of severe malaria, Case control study of death (all cause)
- Where
- 5 sites in Burkina Faso, Côte d’Ivoire and 2 more
- Volunteers
- 2,308 people, healthy volunteers welcome
- Sponsor
- Serum Institute of India Pvt. Ltd.
Malaria
PfSPZ Vaccine: Dose Optimization With Heterologous Challenge in Healthy Malaria-Naïve Adults
This is an open-label evaluation of the safety, tolerability, immunogenicity and efficacy of PfSPZ Vaccine administered by direct venous inoculation (DVI) in healthy, malaria-naïve adult subjects.
- Trial name
- NCT02601716
- Testing
- PfSPZ Vaccine, CHMI (7G8), CHMI (NF135.C10)
- Where
- 2 sites in United States
- Volunteers
- 92 people, healthy volunteers welcome
- Sponsor
- Sanaria Inc.